Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155917 | 1.00 | CCR1 (0.54) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6758127 | 1.00 | CCR1 (0.54) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6156915 | 0.93 | CCR1 (0.52) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6156904 | 0.93 | CCR1 (0.52) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6760369 | 0.93 | CCR1 (0.45) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6158565 | 0.93 | CCR1 (0.45) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6158558 | 0.93 | CCR1 (0.45) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6758130 | 0.91 | PTGDR2 (0.45) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6761418 | 0.91 | CCR1 (0.44) | CCR1PTGDR2EPHX2TSHRMAPT | |
| SCHEMBL6761415 | 0.91 | CCR1 (0.44) | CCR1PTGDR2EPHX2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1525201-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | Pfizer Products Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| WO-2004009588-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | CCR1 1/4885PTGDR2 628/4885EPHX2 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.